|
Study | Country | Drug groups | Number of cases | Findings |
|
Guo et al. [31] | China | Hypertensive patients in ACEIs/ARBs and non-ACEIs/ARBs treatment groups | 3936 | Lower mortality rate |
Megaly et al. [42] | USA | ACEIs/ARBs group | 534 | Lower mortality rate |
Non-ACEIs/ARBs group | 2733 |
|
Salah et al. [46] | USA, Italy | Total patients with hypertension | 16101 | Lower mortality rate |
Patients taking ACEIs or ARBs | 7816 |
|
Wang et al. [47] | China | ACEIs/ARBs group | 8104 | Lower risk of mortality and ventilatory support |
Non-ACEIs/ARBs group | 8203 |
|
Zhang et al. [50] | China | ACEIs/ARBs group | 188 | Lower mortality rate |
Non-ACEIs/ARBs group | 940 |
|
Negreira-Caamaño et al. [45] | Spain | Previous treatment with ACEIs/ARBs | 392 | Lower mortality rate |
No previous treatment with ACEIs/ARBs | 153 |
|
Desai et al. [39] | Italy | Total patients | 575 | Reduced mortality rate in chronic ACEIs users |
ACEIs or ARBs users | 154 |
|
Bae et al. [37] | Korea | RAAS inhibitors users | 1076 | Lower risk of ICU admission |
Never-users of RAAS inhibitors | 298 |
|
Yang et al. [49] | China | ACEIs/ARBs group | 43 | Lower concentrations of hs-CRP and procalcitonin |
Non-ACEIs/ARBs group | 83 |
Controls | 125 |
|
Meng et al. [43] | China | ACEIs/ARBs group | 17 | Decreased IL-6 levels and peak viral load |
Non-ACEIs/ARBs group | 25 |
|
Barochiner et al. [38] | Argentina | Hypertensive patients taking ACEIs or ARBs | 8328 | Lower risk of death, admission to ICU, and mechanical ventilation |
Under other or no treatment | 8983 |
|
Lam et al. [41] | USA | Hypertensive patients | 614 | Lower ICU admission rate and mortality rate |
Meng et al. [44] | China | Hypertensive patients in ACEIs/ARBs group | 73 | Improved clinical outcome such as lower death rate |
Non-ACEIs/ARBs group | 186 |
|
Kim et al. [40] | Korea | ACEIs/ARBs users | 682 | Lower clinical outcomes |
Non-users of ACEIs/ARBs | 603 |
|
Yuan et al. [54] | China | ACEIs/ARBs group | 196 | Protective effects |
Uncontrolled group | 233 |
|
Golpe et al. [51] | Spain | Hypertensive patients with hospital admission | 69 | Lower risk of hospitalization |
Outpatient management | 88 |
|
Semenzato et al. [52] | France | ACEIs/ARBs group | 1524250 | Lower risk of hospitalization and intubation |
CCBs group | 358306 |
|
Tian et al. [55] | China | Discontinued ACEIs/ARBs group | 27 | Discontinued ACEIs/ARBs group had longer hospital stays |
Other antihypertensive drugs group | 26 |
|
Chen et al. [53] | China | RAAS inhibitors group | 355 | Protective effects on mortality |
Non-RAAS inhibitors group | 827 |
|